Treatment methods involving anti‐vascular endothelial growth factor (anti‐VEGF) molecules are utilised for addressing different kinds of significant complications of retinal damage: choroidal neovascularisation and macular edema [2]. The gene discussed is VEGFA; the disease is macular retinal edema.